NorthStar Medical Radioisotopes
Beloit, WI
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (8)
○ EMA GMP
○ MHRA GMP
Quick Facts: NorthStar Medical Radioisotopes
- Signal Score
- 60.0/100
- Quality Compliance
- Assessment pending
- Headquarters
- Beloit, WI
- Modalities
- Ac-225, Cu-67, Lu-177, Radiopharmaceutical CDMO, Clinical and Commercial Dose Manufacturing
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About NorthStar Medical Radioisotopes
Auto-created by AI matchmaker. Data verification pending.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesAc-225, Cu-67, Lu-177, Radiopharmaceutical CDMO, Clinical and Commercial Dose Manufacturing
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
60.0
Broad modality coverage (5 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press8 articles
Broad modality coverage (5 modalities)
Recent News 8 articles
NorthStar opens facility to assist with development and distribution of vital radioisotopes - Radiology Business
NorthStar Medical Radioisotopes Announces Promotion of Jason Vinyard, MBA, MHA, to Vice President, Business Development, Therapeutic Technologies - Business Wire
NorthStar Medical Radioisotopes and YAP Therapeutics Enter into Collaboration Agreement for the Development and Production of Radiopharmaceutical Products - Business Wire
NorthStar Medical Radioisotopes Unveils Radiopharmaceutical Contract Development & Manufacturing (CDMO) Facility - Business Wire
NorthStar launches new CDMO facility - AuntMinnie
Convergent Therapeutics and NorthStar Medical Radioisotopes Announce Expanded Partnership to Support Convergent's Late-Stage Alpha-Emitting Radioantibody Program - BioSpace
NorthStar Medical Radioisotopes Expands Management Team with Appointment of Jean-Noel David, MBA, MS, as Vice President, Operations - Imaging Technology News
NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones - Imaging Technology News
Frequently Asked Questions About NorthStar Medical Radioisotopes
What is NorthStar Medical Radioisotopes's CDMO Signal Score?
NorthStar Medical Radioisotopes has a Signal Score of 60/100, based on quality, operations, financial stability, and capacity data.
Evaluating NorthStar Medical Radioisotopes for a manufacturing program?
Use the free AI matchmaker to compare NorthStar Medical Radioisotopes against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.